Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.

Oncology reports - 1 Apr 2017

Ye Song, Zhao Xin-Yi, Hu Xiao-Ge, Li Tang, Xu Qiu-Ran, Yang Huan-Ming, Huang Dong-Sheng, Yang Liu

Abstract excerpt

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver. Genomic analysis is conducted to identify genetic alterations in driver genes which are all druggable targets for cancer therapy. In the present study, we performed an exome sequencing of 45 driver genes in 100 paired samples from HCC patients including tumors and matched adjacent normal tissues using Illumina HiSeq 2000 platform....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Exome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins c-ret

Share to Sorafenib

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 28350084
DOI: 10.3892/or.2017.5494
PMCID: PMC5367355

Genes

RET
PLCE1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.PMID 28350084Read ↗

Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.Semantic proximity Read ↗

Advances in molecular classification and precision oncology in hepatocellular carcinoma.Semantic proximity Read ↗

Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.Semantic proximity Read ↗

Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapySemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next generation sequencing.Semantic proximity Read ↗

TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 DatabaseSemantic proximity Read ↗

Genetic alterations in hepatocellular carcinoma: An update.Semantic proximity Read ↗

Machine learning and multi-omics data reveal driver gene-based molecular subtypes in hepatocellular carcinoma for precision treatment.Semantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using BioinformaticsSemantic proximity Read ↗

Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.